Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer

Inclusion Criteria:

Patients must have histologically or cytologically confirmed advanced biliary/pancreatic cancer, urothelial cancer, or non-small cell lung cancer that is metastatic or unresectable
Patients with known CNS metastases should be excluded from this clinical trial
ECOG performance status ≤ 2 (Karnofsky ≥ 60%)
Life expectancy of greater than 12 weeks
Absolute neutrophil count ≥ 1,500/mcL
Platelets ≥ 100,000/mcL
Total bilirubin within normal institutional limits
AST/ALT ≤ 2.5 times institutional upper limit of normal
Creatinine within normal institutional limits OR creatinine clearance ≥ 60 mL/min
QTc interval on ECG ≤ 0.48 seconds by Bazett's calculation (≤ CTCAE v.4 grade 2)
Not pregnant or nursing
Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation
Patients must be able to swallow pills and have no significant impairment in gastrointestinal absorption

Patients with known or suspected germline mutation in BRCA1 or BRCA2 are eligible to participate

Patients in study screening (primarily those with pancreatic cancer) who have a family history that is suspicious for BRCA1 or BRCA2 germline mutation should be assessed by the BRCAPRO computer program to quantitate the likelihood of harboring a deleterious BRCA mutation
Patients found to have a BRCAPRO probability score of ≥ 20% should undergo formal full-sequence BRCA testing
Patients in screening with a BRCAPRO probability of ≥ 20% who decline genetic testing are not eligible to participate in this trial due to the potential to confound safety assessment

No uncontrolled intercurrent illness including, but not limited to:

Ongoing or active infection
Symptomatic congestive heart failure
Unstable angina pectoris
Cardiac arrhythmia
Psychiatric illness/social situations that would limit compliance with study requirements
HIV-positive patients are eligible
No active seizure or history of seizure disorder
No history of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib (ABT-888) or other agents used in this study
No peripheral neuropathy greater than grade1
No prior systemic treatment
No prior cytotoxic chemotherapy (neoadjuvant, adjuvant, or metastatic setting)
At least 4 weeks since major surgery or radiation therapy
Patients may not be receiving any other investigational agents